AnaptysBio, Inc. (ANAB) Coverage Initiated by Analysts at SunTrust Banks, Inc.
SunTrust Banks, Inc. initiated coverage on shares of AnaptysBio, Inc. (NASDAQ:ANAB) in a research report sent to investors on Wednesday morning. The brokerage issued a buy rating and a $115.00 target price on the biotechnology company’s stock.
A number of other brokerages have also issued reports on ANAB. Royal Bank Of Canada raised their price objective on shares of AnaptysBio from $40.00 to $79.00 and gave the company an outperform rating in a report on Tuesday, October 10th. Credit Suisse Group raised their price objective on shares of AnaptysBio from $38.00 to $85.00 and gave the company an outperform rating in a report on Tuesday, October 10th. Robert W. Baird set a $69.00 price objective on shares of AnaptysBio and gave the company a buy rating in a report on Wednesday, October 11th. Zacks Investment Research lowered shares of AnaptysBio from a buy rating to a hold rating in a report on Wednesday, October 11th. Finally, Stifel Nicolaus reiterated a buy rating and issued a $76.00 price objective (up previously from $35.00) on shares of AnaptysBio in a report on Friday, October 13th. One equities research analyst has rated the stock with a hold rating and eight have issued a buy rating to the company. The stock currently has a consensus rating of Buy and an average target price of $84.78.
AnaptysBio (ANAB) traded up $2.97 during mid-day trading on Wednesday, hitting $74.86. 507,019 shares of the stock were exchanged, compared to its average volume of 205,320. The company has a debt-to-equity ratio of 0.09, a current ratio of 10.77 and a quick ratio of 10.77. AnaptysBio has a 52-week low of $15.17 and a 52-week high of $78.98.
AnaptysBio (NASDAQ:ANAB) last posted its earnings results on Tuesday, November 7th. The biotechnology company reported ($0.45) EPS for the quarter, topping analysts’ consensus estimates of ($0.47) by $0.02. analysts anticipate that AnaptysBio will post -1.72 EPS for the current year.
In other AnaptysBio news, major shareholder Holdings A/S Novo sold 356,300 shares of the stock in a transaction that occurred on Monday, August 21st. The shares were sold at an average price of $21.10, for a total transaction of $7,517,930.00. Following the completion of the sale, the insider now owns 1,936,604 shares of the company’s stock, valued at approximately $40,862,344.40. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.
Large investors have recently added to or reduced their stakes in the business. Evercore Wealth Management LLC acquired a new stake in AnaptysBio during the 3rd quarter valued at approximately $100,000. Legal & General Group Plc increased its position in AnaptysBio by 160.8% during the 3rd quarter. Legal & General Group Plc now owns 3,164 shares of the biotechnology company’s stock valued at $110,000 after purchasing an additional 1,951 shares during the period. Bank of America Corp DE acquired a new stake in AnaptysBio during the 1st quarter valued at approximately $123,000. DAFNA Capital Management LLC increased its position in AnaptysBio by 22.2% during the 2nd quarter. DAFNA Capital Management LLC now owns 5,500 shares of the biotechnology company’s stock valued at $132,000 after purchasing an additional 1,000 shares during the period. Finally, Nationwide Fund Advisors increased its position in AnaptysBio by 89.5% during the 3rd quarter. Nationwide Fund Advisors now owns 5,878 shares of the biotechnology company’s stock valued at $205,000 after purchasing an additional 2,776 shares during the period. 59.04% of the stock is owned by institutional investors and hedge funds.
AnaptysBio Company Profile
AnaptysBio, Inc is a United States-based biotechnology company. The Company is engaged in developing antibody product candidates focused on unmet medical needs in inflammation and immuno-oncology. The Company develops its product candidates using its antibody discovery technology platform, which is designed to replicate, in vitro, the natural process of antibody generation.
Receive News & Ratings for AnaptysBio Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AnaptysBio Inc. and related companies with MarketBeat.com's FREE daily email newsletter.